Showing 5321-5330 of 7023 results for "".
- Tik Tok Trend Watch: Cyanide as a Potential Acne Cure?https://practicaldermatology.com/news/tik-tok-trend-watch-cyanide-as-a-potential-acne-cure/2461968/Tik Tok is where many trends and DIY challenges get started, and skin care one of the more popular categories for this content. The latest -- a viral video of a woman claiming that she has been 'secretly' feeding her boyfriend seeds containing cyanide (yes, that cyani
- New CEO for SciBasehttps://practicaldermatology.com/news/new-ceo-for-scibase/2461967/Pia Renaudin is SciBase’s new Chief Executive Officer (CEO), effective October 1st, 2023. SciBase's products include Nevisense and Nevisense Go and address melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Ms.
- Time Matters When Saving Skin During FLASH Radiotherapyhttps://practicaldermatology.com/news/time-matters-when-saving-skin-during-flash-radiotherapy/2461966/Multiple beams and intervals in delivery during FLASH proton therapy treatment may reduce skin-saving effects in preclinical models, according to a study in the International Journal of Radiation
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval cove
- China's NMPA Accepts Akeso’s NDA for Ebdarokimab in Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/chinas-nmpa-accepts-akesos-nda-for-ebdarokimab-in-moderate-to-severe-plaque-psoriasis/2461958/Akeso Inc.’s New Drug Application (NDA) for its fully human IgG1monoclonal antibody ebdarokimab (IL-12/lL-23, AK101) for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted by the National Center for Drug Evaluation of the State Drug Administration of the
- New Platform May Help Determine Which Melanoma Patients Will Respond to Immunotherapyhttps://practicaldermatology.com/news/new-platform-may-help-determine-which-melanoma-patients-will-respond-to-immunotherapy/2461949/A new approach that integrates a minimally invasive, painless microneedle platform may help monitor protein biomarkers in responses to a combination immunotherapy against melanoma. The platform is capable of absorbing the cell-surrounding, biomarker-containing fluid from deeper layers o
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- Wristbands May Be Home to E. coli, Staphhttps://practicaldermatology.com/news/wristbands-may-be-home-to-e-coli-staphylococcus/2461937/Common wristbands can be ‘hotbed’ for harmful bacteria including E. coli, staphylococcus, according to new research. Researchers from Florida Atlantic University’s Charles E. Schmidt Colleg
- Leprosy Cases Rise in Florida: What Do Dermatologists Need to Know?https://practicaldermatology.com/news/leprosy-cases-rise-in-florida-what-do-dermatologists-need-to-know/2461935/Leprosy is making headlines because of an outbreak in Florida, and although this disease is still rare, it should be on dermatologists' radar, says Carrie Kovarik, MD, a professor of dermatology and medicine at Perelman School of Medicine at the University of Pennsylvania in Philadelphia
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of